Make Informed Investment Decisions with Affordable Access to Experts
A 5th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)Ticker(s): GBT, Emmaus Life Sciences
Name: Dr Julie Kanter - MD
- Associate Professor of Hematology at the University of Alabama at Birmingham and oversees the Adult Sickle Cell Clinic.
- Currently manages 1000 - 1100 patients with sickle cell disease.
- Principal Investigator in a number of large clinical trials related to sickle cell disease and has been involved in the comprehensive care and research for sickle cell disease patients for the past 10 years.
Please describe your background and experience with Sickle Cell Disease and any work with Voxelotor.Added By: c_admin
What is your high level opinion of today's top-line HOPE trial data?Added By: c_admin
On a scale of 1-10 how excited about this program are you for patients?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.